Navigation Links
Verenium To Present At The Rodman & Renshaw Annual Global Investment Conference
Date:9/4/2013

ully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2012 and any updates contained in its subsequently filed quarterly reports on Form 10-Q.  These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.

Contacts:

Sarah Carmody
Sr. Manager, Corporate Communications
858-431-8581
sarah.carmody@verenium.com


'/>"/>
SOURCE Verenium Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
2. Verenium to Present at Baird Clean Technology Conference
3. First Product Candidate Moving Toward Commercialization as Result of Novus International and Verenium Collaboration
4. Verenium Corporation to Announce Fourth Quarter and Year-End 2011 Financial Results
5. Verenium Corporation To Announce First Quarter 2012 Financial Results
6. Verenium Corporation Named One Of The 2012 Best Places to Work in San Diego
7. Verenium Corporation And Alexandria Real Estate Equities, Inc. Celebrate The Grand Opening Of A New State-of-the-art Biotechnology Facility
8. Verenium Announces EPA Authorization To Market Its Next-Generation Enzyme Breaker For Hydraulic Fracturing
9. Verenium Corporation To Announce Second Quarter 2012 Financial Results
10. Verenium Reports Financial Results For The Second Quarter And Six Months Ended June 30, 2012
11. Verenium Corporation To Announce Third Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... , Alemania, April 27, 2015 ... nuevo receptor utilizando tecnología de descubrimiento de biomarcador computacional  ... el tratamiento de millones de pacientes con cáncer   ... ha recibido una patente en Europa titulada "Tissue Protective ... Molecular Health de que EPHB4 es un nuevo receptor ...
(Date:4/27/2015)... 2015 Deadly viruses such as Ebola ... of the University City Science Center's Port ... , With a $4.5 million Phase 2 SBIR grant ... Phelix Therapeutics is focused on therapies for unmet ... company is developing first-in-class protease inhibitors based on a ...
(Date:4/27/2015)... , April 27, 2015   Aratana ... pet therapeutics company focused on the licensing, development ... animals, today provided commentary on clinical study data ... a poster session at the American Association for ... ADXS31-164 is a novel Lm -LLO immunotherapy ...
(Date:4/27/2015)... HEIDELBERG , Germany , April ... need in treatment of millions of cancer patients   ... a patent in Europe entitled ... Health,s discovery that EPHB4 is a novel receptor for Erythropoietin ... stimulates the production of red blood cells and is ...
Breaking Biology Technology:Molecular Health obtiene la patente para un nuevo receptor 2Molecular Health obtiene la patente para un nuevo receptor 3New Resident of Science Center’s Port Business Incubator Targets SARS and Ebola 2Aratana Therapeutics Comments on ADXS31-164 (AT-014) Study Data Presented During Poster Session at the American Association for Cancer Research (AACR) Annual Meeting 2015 2Molecular Health Gains Patent for Novel Receptor Utilizing Computational Biomarker Discovery Technology 2
... Symbol: MSEDMONTON, April 14 /PRNewswire-FirstCall/ - BioMS Medical Corp. ... multiple sclerosis (MS), today announced that the independent Data ... phase III MAESTRO-03 trial of dirucotide in patients with ... recommended that the trial continue as per the protocol. ...
... Therapeutics, Inc., the leader in fragment-based lead discovery ... successful completion of the first phase of its ... of Biogen Idec (Nasdaq: BIIB ). ... to Zenobia,s technology and expertise in structural biology, ...
... Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) ... fiscal 2009 third quarter and nine-month period ended February ... its fiscal year 2009 now ending on February, 28. ... ended February 28, 2009 in the range of $3,400,000 ...
Cached Biology Technology:BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board 2Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals 2Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 2Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 3Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 4Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 5
(Date:4/2/2015)... , April 2, 2015 ... DERMALOG by far outperforms the strongest competitors, showing ... high accuracy, the system is capable of a ... speed proves up to be ten times faster ... its runner-up performance.      (Photo: ...
(Date:4/1/2015)... Medisafe ™, the leading global medication management platform with ... Android smartphones and tablets, announces today that ... allow patients to track and correlate their adherence directly ... be able to visualize in real-time how taking medication ... glucose levels and blood pressure. "Patients need ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... from layers 3.46 billion years old suggests that not only ... atmosphere was as oxygen rich as it is today, according ... ways similar to the way this rock forms around hydrothermal ... have assumed that the hematite in ancient rocks formed by ...
... scientists from the National Institute of Oceanography and the ... research vessel Polarstern. The cooperative project Lohafex has yielded ... has dampened hopes on the potential of the Southern ... 2 ) and thus mitigate global warming. On 17 ...
... a common ingredient in over-the-counter skin creams. Recent results ... it is associated with major environmental risks. , "The ... in the ocean that has a direct impact on ... Porsbring. When Euorpean authorities assess environmental risks, they ...
Cached Biology News:Deep-sea rocks point to early oxygen on Earth 2Lohafex provides new insights on plankton ecology 2Lohafex provides new insights on plankton ecology 3Lohafex provides new insights on plankton ecology 4Drug used to treat skin conditions is a marine pollutant 2
... ApopTag Fluorescein Direct In Situ ... cells in situ by the ... fragments are tagged with a ... kit provides fluorescence staining for ...
... The CHEMICON APO-BRDU Kit is ... DNA breaks and total cellular DNA to ... The kit contains the instructions and reagents ... positive and negative control cells for assessing ...
The stirbar is used in the buffer tank of the Trans-Blot Plus cell to maintain uniform conductivity and temperature during electrophoretic transfer. Dimensions are 3.5 x 0.5 in....
... FXP is the latest entry in the Biomek ... accuracy and increased robustness, it can meet the ... be configured with either one or two pipetting ... FXP sets the standard for flexible laboratory solutions ...
Biology Products: